Get the Stockscreener App
7.21
0.96%
-0.07
Sage Therapeutics Inc stock is traded at $7.21, with a volume of 588.00K.
It is down -0.96% in the last 24 hours and up +20.57% over the past month.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$7.28
Open:
$7.26
24h Volume:
588.00K
Relative Volume:
0.38
Market Cap:
$445.34M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
-0.8594
EPS:
-8.39
Net Cash Flow:
$-424.74M
1W Performance:
-0.55%
1M Performance:
+20.57%
6M Performance:
-13.24%
1Y Performance:
-69.85%
1-Day Range:
$7.20
$7.31
1-Week Range:
$6.99
$7.32
52-Week Range:
$4.62
$27.39
Sage Therapeutics Inc Stock (SAGE) Company Profile
Name
Sage Therapeutics Inc
Sector
Industry
Phone
617-299-8380
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare SAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
7.21 | 445.34M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.22 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.97 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.68 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-04-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-29-24 | Initiated | Citigroup | Sell |
| May-29-24 | Initiated | Robert W. Baird | Neutral |
| Apr-17-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Aug-08-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-08-23 | Downgrade | Goldman | Buy → Neutral |
| Aug-08-23 | Downgrade | Needham | Buy → Hold |
| Aug-07-23 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-07-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-07-23 | Downgrade | Stifel | Buy → Hold |
| Aug-07-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Mar-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Mar-31-22 | Initiated | Berenberg | Hold |
| Nov-02-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-16-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-07-21 | Initiated | Piper Sandler | Overweight |
| Feb-26-21 | Downgrade | Mizuho | Buy → Neutral |
| Feb-25-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Resumed | Raymond James | Mkt Perform |
| Jan-22-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-04-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-04-20 | Upgrade | Mizuho | Neutral → Buy |
| Dec-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-06-20 | Reiterated | H.C. Wainwright | Neutral |
| Sep-11-20 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-10-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-08-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-28-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-06-19 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-05-19 | Reiterated | Guggenheim | Buy |
| Dec-05-19 | Downgrade | SunTrust | Buy → Hold |
| Oct-30-19 | Initiated | H.C. Wainwright | Neutral |
| May-23-19 | Initiated | Wedbush | Outperform |
| Apr-25-19 | Initiated | Jefferies | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-11-18 | Initiated | Oppenheimer | Outperform |
View All
Sage Therapeutics Inc Stock (SAGE) Latest News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect - Markets Insider
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - Markets Insider
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Sage Therapeutics (SAGE) Projected to Post Earnings on Tuesday - MarketBeat
FY2025 Earnings Forecast for SAGE Issued By Leerink Partnrs - MarketBeat
Key deals this week: Molson Coors Beverage, Emerson Electric, Sage Therapeutics and more - MSN
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok - Benzinga
Vanguard Group Inc Reduces Stake in Sage Therapeutics Inc - GuruFocus.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation - Markets Insider
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up - MSN
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates - MSN
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Reach Out - Markets Insider
SAGESage Therapeutics, Inc Latest Stock News & Market Updates - StockTitan
Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 - Business Wire
Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart
Postpartum Depression Market Expected to rise, 2034 | Pfizer, - openPR
Sage rejects Biogen takeover and launches review - pharmaphorum
Sage Rejects Biogen Bid but Could be Open to Other Offers - TipRanks
Sage Spurns Biogen, Turns Attention To Strategic Review - News & Insights
Sage Therapeutics rejects Biogen bid, starts strategic review - MSN
Sage rejects Biogen’s buyout offer, but says it's open to deals - The Business Journals
Sage Therapeutics shares rise amid strategic review - Investing.com
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company - Reuters
Sage Therapeutics Turns Down Biogen's Unsuitable OfferNews and Statistics - IndexBox, Inc.
Sage Therapeutics rejects Biogen bid, starts strategic review (SAGE:NASDAQ) - Seeking Alpha
Sage Therapeutics shares rise amid strategic review By Investing.com - Investing.com South Africa
Sage rejects Biogen's takeover offer, to explore strategic alternatives -January 27, 2025 at 09:28 am EST - Marketscreener.com
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives -January 27, 2025 at 09:20 am EST - Marketscreener.com
FY2024 EPS Estimates for Sage Therapeutics Lifted by Wedbush - MarketBeat
SAGE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
JPMorgan Chase & Co. Decreases Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm - GlobeNewswire Inc.
FY2029 Earnings Estimate for SAGE Issued By Wedbush - MarketBeat
Sage Therapeutics Looks Like A 'Strong Buy' With Zurzuvae's Potential & Biogen's Bid - Seeking Alpha
How To Trade (SAGE) - Stock Traders Daily
Sage Sues Partner Biogen After Unsolicited Takeover Offer - BioSpace
Sage sues Biogen after unsolicited takeover bid - pharmaphorum
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid - MSN
Sage sues Biogen in wake of $469M buyout offer: report (BIIB:NASDAQ) - Seeking Alpha
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1) - Bloomberg Law
BB Biotech AG Significantly Reduces Stake in Sage Therapeutics I - GuruFocus.com
Biogen Offers to Buy Remaining Stake in Sage Therapeutics - MSN
Sage Therapeutics, Inc. (NASDAQ:SAGE) Short Interest Down 24.6% in December - MarketBeat
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders - Seeking Alpha
Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen - MSN
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last? - MSN
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In - MSN
Sage Therapeutics Inc Stock (SAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):